(12) **Translation of European patent specification**

(11) **NO/EP 2842573 B1**

NORWAY

(19) NO

(51) Int Cl.

C07K 16/28 (2006.01)

A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.02.12
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.09.27
(86)	European Application Nr.	14188785.1
(86)	European Filing Date	2009.11.06
(87)	The European Application's Publication Date	2015.03.04
(30)	Priority	2008.11.07, US, 112686 P 2009.03.30, US, 164870 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2365828, filing date 2009.11.06
(73)	Proprietor	Galaxy Biotech, LLC, 22830 San Juan Road, Cupertino CA 95014, US-USA
(72)	Inventor	Kim, Kyung Jin, 22830 San Juan Road, Cupertino, CA 95014, US-USA Zhao, Wei-Meng, 104 Windsor Drive, San Carlos, CA 94070, US-USA Park, Hangil, 18 Mounds Rd. 3, San Mateo, CA 94402, US-USA
(74)	Agent or Attorney	CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54) Title **Monoclonal antibodies to Fibroblast Growth Factor receptor 2**

(56) References Cited:

US-A1- 2007 248 605, ZHAO WEI-MENG ET AL: "Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts", CLINICAL CANCER RESEARCH, vol. 16, no. 23, December 2010 (2010-12), pages 5750-5758, XP002673994, ISSN: 1078-0432, MASAYUKI TAKEDA ET AL: "AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over- Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 10, 15 May 2007 (2007-05-15), pages 3051-3057, XP008138953, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-2743, WEI PING ET AL: "Generation and characterization of monoclonal antibodies to human keratinocyte growth factor receptor", HYBRIDOMA, vol. 25, no. 3, June 2006 (2006-06), pages 115-124, XP002673993, ISSN: 1554-0014

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav.

1. Humanisert, humant eller genetisk manipulert monoklonalt antistoff (mAb) som binder FGFR2IIIb men ikke FGFR2IIIc og inhiberer vekst av et humant tumorxenotransplantat i en mus hvori nevnte mAb

(i) konkurrerer om binding til FGFR2 med monoklonalt antistoff GAL-FR21 deponert under ATCC-nummer PTA-9586, og

(ii) inhiberer binding av FGF2, FGF7 og FGF10 til FGFR2IIIb.

2. mAb ifølge krav 1 som er et Fab- eller $F(ab')_2$-fragment eller enkelt-kjedet antistoff.

3. mAb ifølge krav 1 eller 2 som konkurrerer om binding til FGFR2 med monoklonalt antistoff GAL-FR21 deponert under ATCC-nummer PTA-9586, hvori nevnte mAb er genetisk manipulert.

4. mAb ifølge krav 3 som inhiberer vekst av et SNU-16 humant tumorxenotransplantat i en mus.

5. mAb ifølge 3 som er kimert eller humanisert.

6. mAb ifølge krav 3 som er humant.

7. Farmasøytisk blanding som omfatter mAb ifølge krav 1.

8. mAb ifølge krav 1 for anvendelse i behandlingen av kreft.

9. mAb ifølge krav 8 for anvendelse ifølge krav 8, hvori kreften er en gastrisk kreft.